Please login to the form below

Not currently logged in
Email:
Password:

neurodegenerative diseases

This page shows the latest neurodegenerative diseases news and features for those working in and with pharma, biotech and healthcare.

J&J bolsters gene therapy unit with $100m MeiraGTx deal

J&J bolsters gene therapy unit with $100m MeiraGTx deal

MeiraGTx is also working on gene therapies for salivary gland problems and neurodegenerative diseases. ... The companies will also work together on new targets for other inherited retinal diseases and on adeno-associated virus (AAV) manufacturing

Latest news

More from news
Approximately 3 fully matching, plus 46 partially matching documents found.

Latest Intelligence

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    The Dementia Consortium provides academic researchers with the funding, industry expertise and project management resources to capitalise on new drug targets for the treatment of the neurodegenerative diseases that cause dementia. ... Diseases include

  • Key considerations for disease- modifying Parkinson’s disease trials Key considerations for disease- modifying Parkinson’s disease trials

    The design of such neuroprotective studies may benefit from the lessons learned in studies in the most common neurodegenerative disease, Alzheimer’s. ... Target early disease stages: It is probably true for all neurodegenerative diseases that symptoms

  • Deal Watch January 2018

    Takeda moves in neurodegenerative diseases and stem cell therapy. Meanwhile Takeda, ranked 4. ... Denali had also been busy having completed a $250m IPO in early December.  The company has a focus in neurodegenerative diseases and a technology,

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Out-partnering deals included the $1.1bn licence to LEO for tralokinumab in skin diseases and the $1bn divestment to Pfizer of its late-stage small molecule anti-infective business. ... These deals were mainly early stage deals in the areas of

  • Deal Watch December 2016 Deal Watch December 2016

    510. Nuevolution (Denmark). Almirall (Spain). Research collaboration. RORγt inhibitors for inflammatory skin diseases and psoriatic arthritis. ... 320. Evotec (Germany). Celgene (US). Discovery collaboration. Induced pluripotent stem cells for

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics